CN1154635C - 具有止痛作用的新化合物 - Google Patents

具有止痛作用的新化合物 Download PDF

Info

Publication number
CN1154635C
CN1154635C CNB971808376A CN97180837A CN1154635C CN 1154635 C CN1154635 C CN 1154635C CN B971808376 A CNB971808376 A CN B971808376A CN 97180837 A CN97180837 A CN 97180837A CN 1154635 C CN1154635 C CN 1154635C
Authority
CN
China
Prior art keywords
compound
formula
mixture
definition
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB971808376A
Other languages
English (en)
Chinese (zh)
Other versions
CN1241178A (zh
Inventor
B
B·佩尔曼
E·罗伯特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca Canada Inc
Original Assignee
Astra Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Inc filed Critical Astra Pharma Inc
Publication of CN1241178A publication Critical patent/CN1241178A/zh
Application granted granted Critical
Publication of CN1154635C publication Critical patent/CN1154635C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
CNB971808376A 1996-12-20 1997-12-09 具有止痛作用的新化合物 Expired - Fee Related CN1154635C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9604786-5 1996-12-20
SE9604786A SE9604786D0 (sv) 1996-12-20 1996-12-20 New compounds
SE96047865 1996-12-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2004100324204A Division CN1539824A (zh) 1996-12-20 1997-12-09 具有止痛作用的新化合物

Publications (2)

Publication Number Publication Date
CN1241178A CN1241178A (zh) 2000-01-12
CN1154635C true CN1154635C (zh) 2004-06-23

Family

ID=20405139

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB971808376A Expired - Fee Related CN1154635C (zh) 1996-12-20 1997-12-09 具有止痛作用的新化合物
CNA2004100324204A Pending CN1539824A (zh) 1996-12-20 1997-12-09 具有止痛作用的新化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2004100324204A Pending CN1539824A (zh) 1996-12-20 1997-12-09 具有止痛作用的新化合物

Country Status (31)

Country Link
US (3) US6153626A (https=)
EP (2) EP1428821A1 (https=)
JP (1) JP2001507021A (https=)
KR (1) KR20000069600A (https=)
CN (2) CN1154635C (https=)
AR (1) AR010378A1 (https=)
AT (1) ATE266638T1 (https=)
AU (1) AU738002B2 (https=)
BR (1) BR9713785A (https=)
CA (1) CA2274117A1 (https=)
CZ (1) CZ220099A3 (https=)
DE (1) DE69729115T2 (https=)
DK (1) DK0946510T3 (https=)
EE (1) EE03966B1 (https=)
ES (1) ES2219783T3 (https=)
HU (1) HUP0000613A3 (https=)
ID (1) ID21662A (https=)
IL (1) IL130536A0 (https=)
IS (1) IS5078A (https=)
MY (1) MY132705A (https=)
NO (1) NO313632B1 (https=)
NZ (1) NZ336028A (https=)
PL (1) PL188945B1 (https=)
PT (1) PT946510E (https=)
RU (1) RU2193030C2 (https=)
SE (1) SE9604786D0 (https=)
SK (1) SK283300B6 (https=)
TR (1) TR199901411T2 (https=)
UA (1) UA54481C2 (https=)
WO (1) WO1998028270A1 (https=)
ZA (1) ZA9711049B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9604786D0 (sv) * 1996-12-20 1996-12-20 Astra Pharma Inc New compounds
US6974825B1 (en) 1996-12-20 2005-12-13 Astrazeneca Canada Inc. Compounds with analgesic effect
TW548271B (en) * 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
EP1049676B1 (en) * 1997-12-24 2005-10-12 Ortho-Mcneil Pharmaceutical, Inc. 4- aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor
AU2003220725B2 (en) * 1997-12-24 2006-06-01 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor
EP1512683B1 (en) * 1998-03-10 2011-08-31 Research Triangle Institute Novel opiate compounds, methods of making and methods of use
US6900228B1 (en) * 1998-03-10 2005-05-31 Research Triangle Institute Opiate compounds, methods of making and methods of use
US6436959B1 (en) 1998-12-23 2002-08-20 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)]aminobenzamides
SE9904673D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE9904675D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE9904674D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
EP1242421A1 (en) 1999-12-22 2002-09-25 Ortho-McNeil Pharmaceutical, Inc. 4-[aryl(8-azabicyclo[3.2.1] octan-3-yl)] aminobenzoic acid derivatives
US6916822B2 (en) * 2000-02-18 2005-07-12 Meiji Seika Kaisha, Ltd. Phenoxyalkylamine derivatives useful as opioid δ receptor agonists
IL151550A0 (en) 2000-03-03 2003-04-10 Ortho Mcneil Pharm Inc 3-(diarylmethylene)-8-azabicyclo [3.2.1] octane derivatives
CA2404280A1 (en) 2000-03-24 2002-09-23 Meiji Seika Kaisha, Ltd. Diphenylalkylamine derivatives useful as opioid .delta. receptor agonists
SE0001209D0 (sv) 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
WO2002048122A2 (en) * 2000-12-14 2002-06-20 Ortho-Mcneil Pharmaceutical, Inc. Benzamidine derivatives
CN1258529C (zh) * 2000-12-15 2006-06-07 阿斯特拉曾尼卡有限公司 制备二芳基－4－氨基－哌啶基化合物的方法
SE0101769D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
SE0101770D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
PT1395567E (pt) 2001-05-18 2009-03-26 Astrazeneca Ab Derivados de 4(fenil-piperazinil-metil)benzamida e sua utilização para o tratamento da ansiedade da dor ou de distúrbios gastrointestinais
SE0101771D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
SE0101773D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
EA006507B1 (ru) 2001-10-15 2005-12-29 Янссен Фармацевтика Н.В. Новые замещенные 4-фенил-4-[1h-имидазол-2-ил] пиперидиновые производные и их применение в качестве селективных непептидных агонистов дельта-опиоидов
MXPA04008797A (es) * 2002-03-13 2004-11-26 Janssen Pharmaceutica Nv Inhibidores de histona desacetilasa.
NZ566263A (en) 2002-05-24 2009-09-25 Millennium Pharm Inc CCR9 inhibitors and methods of use thereof
SE0203300D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203303D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203302D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
KR100874292B1 (ko) 2002-11-18 2008-12-18 케모센트릭스 아릴 술폰아마이드
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
PT1587789E (pt) * 2003-01-16 2008-12-16 Acadia Pharm Inc Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas
AU2004253898A1 (en) 2003-06-27 2005-01-13 Janssen Pharmaceutica N.V. Tricyclic delta opioid modulators
US7435822B2 (en) 2004-02-03 2008-10-14 Janssen Pharmaceutica N.V. 3-(diheteroarylmethylene)-8-azabicyclo[3.2.1]octane and 3-((aryl)(heteroaryl)methylene)-8-azabicyclo[3.2.1]octane derivatives
KR101234421B1 (ko) 2004-08-02 2013-02-18 아스트라제네카 아베 디아릴메틸 피페라진 유도체, 이의 제조 방법 및 용도
WO2007030089A1 (en) * 2004-08-05 2007-03-15 Janssen Pharmaceutica N.V. Tricyclic delta- opioid modulators
MX2007007625A (es) * 2004-12-22 2008-01-28 Johnson & Johnson Moduladores delta-opioides triciclicos.
EA011674B1 (ru) * 2004-12-22 2009-04-28 Янссен Фармацевтика Н.В. ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ
BRPI0519201A2 (pt) * 2004-12-22 2008-12-30 Janssen Pharmaceutica Nv moduladores de delta-opiàide tricÍclico
AU2006203880A1 (en) * 2005-01-06 2006-07-13 Janssen Pharmaceutica N.V. Tricyclic delta-opioid modulators
TWI449692B (zh) 2005-05-13 2014-08-21 Otsuka Pharma Co Ltd 吡咯烷化合物（三）
JP2008543866A (ja) * 2005-06-16 2008-12-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 三環式オピオイドモジュレーター
JP5219465B2 (ja) * 2006-11-10 2013-06-26 大塚製薬株式会社 医薬

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4091096A (en) * 1976-03-19 1978-05-23 Eli Lilly And Company Dinitroanilines for the control of phytopathogens
EG12406A (en) * 1976-08-12 1979-03-31 Janssen Pharmaceutica Nv Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides
SE441448B (sv) * 1977-05-23 1985-10-07 Pfizer Sett att framstella hexahydro-gamma-karbolinforeningar
DE3200304A1 (de) * 1981-01-16 1982-08-26 Sandoz-Patent-GmbH, 7850 Lörrach 3-aminopropoxyaryl-derivate, ihre herstellung und sie enthaltende arzneimittel
EP0181793B1 (fr) * 1984-10-16 1988-07-27 Synthelabo Dérivés de pipéridine, leur préparation et leur application en thérapeutique
YU150489A (sh) 1989-08-10 1992-12-21 W.L. Gore & Co. Gmbh. Uređaj za ispitivanje odevnih predmeta na nepromočivost
KR940003491B1 (ko) 1989-08-10 1994-04-23 리히터 게데온 베기에스제티 기아르 알.티 4,4-이중 치환된 피페리딘 유도체와 그 제조방법 및 상기 화합물을 함유하는 약제학적 조성물
SE8904298D0 (sv) * 1989-12-21 1989-12-21 Astra Ab New compounds
GB9202238D0 (en) * 1992-02-03 1992-03-18 Wellcome Found Compounds
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
SE9604786D0 (sv) 1996-12-20 1996-12-20 Astra Pharma Inc New compounds
TW548271B (en) * 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
EP1049676B1 (en) * 1997-12-24 2005-10-12 Ortho-Mcneil Pharmaceutical, Inc. 4- aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor
EP1512683B1 (en) 1998-03-10 2011-08-31 Research Triangle Institute Novel opiate compounds, methods of making and methods of use
US6436959B1 (en) 1998-12-23 2002-08-20 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)]aminobenzamides

Also Published As

Publication number Publication date
WO1998028270A1 (en) 1998-07-02
IS5078A (is) 1999-06-11
HUP0000613A2 (hu) 2000-09-28
EP0946510B1 (en) 2004-05-12
IL130536A0 (en) 2000-06-01
EE9900261A (et) 2000-02-15
AU738002B2 (en) 2001-09-06
HK1022910A1 (en) 2000-08-25
SK283300B6 (sk) 2003-05-02
EE03966B1 (et) 2003-02-17
EP1428821A8 (en) 2005-01-26
MY132705A (en) 2007-10-31
TR199901411T2 (xx) 1999-09-21
JP2001507021A (ja) 2001-05-29
CN1241178A (zh) 2000-01-12
SE9604786D0 (sv) 1996-12-20
US6399635B1 (en) 2002-06-04
AU5351398A (en) 1998-07-17
CN1539824A (zh) 2004-10-27
ZA9711049B (en) 1998-06-22
PL334370A1 (en) 2000-02-28
ATE266638T1 (de) 2004-05-15
NO993023L (no) 1999-08-12
EP0946510A1 (en) 1999-10-06
PT946510E (pt) 2004-08-31
RU2193030C2 (ru) 2002-11-20
CZ220099A3 (cs) 1999-11-17
KR20000069600A (ko) 2000-11-25
EP1428821A1 (en) 2004-06-16
UA54481C2 (uk) 2003-03-17
US20030055045A1 (en) 2003-03-20
CA2274117A1 (en) 1998-07-02
HUP0000613A3 (en) 2002-10-28
DE69729115D1 (de) 2004-06-17
NO313632B1 (no) 2002-11-04
US6153626A (en) 2000-11-28
NZ336028A (en) 2001-03-30
PL188945B1 (pl) 2005-05-31
DK0946510T3 (da) 2004-08-09
AR010378A1 (es) 2000-06-07
ID21662A (id) 1999-07-08
ES2219783T3 (es) 2004-12-01
DE69729115T2 (de) 2005-04-28
NO993023D0 (no) 1999-06-18
US6710179B2 (en) 2004-03-23
HK1023996A1 (en) 2000-09-29
SK76399A3 (en) 2000-01-18
BR9713785A (pt) 2000-02-08

Similar Documents

Publication Publication Date Title
CN1154635C (zh) 具有止痛作用的新化合物
CN1146540C (zh) 具有镇痛作用的新化合物及其用途
CN1118452C (zh) 1－[(1－取代－4－哌啶基)甲基]－4－哌啶衍生物、其生产方法、含有该化合物的药物组合物和这些化合物的中间体
CN1111529C (zh) 作为神经激肽拮抗剂的哌嗪子基衍生物
CN1056605C (zh) 作为人速激肽ⅲ受体的选择性拮抗剂的化合物及其用途
CN1041420C (zh) Ｎ－酰基－２，３－苯并环二氮杂䓬衍生物的制备方法
CN1319973C (zh) 哌啶衍生物
CN1143848C (zh) 用作毒蕈碱性受体拮抗剂的2-芳基乙基-(哌啶-4-基甲基)胺衍生物
CN1229373C (zh) 作为神经激肽1拮抗剂的哌啶衍生物
CN1094723A (zh) 羧酰胺衍生物
CN1703403A (zh) 趋代谢的谷氨酸盐受体拮抗剂
CN1094727A (zh) 5-芳基吲哚衍生物
CN1035178C (zh) 芳酰胺衍生物
CN1668585A (zh) 用作蝇蕈碱受体拮抗剂的3,6－二取代氮杂双环[3.1.0]己烷衍生物
CN1890208A (zh) 类鸦片受体拮抗剂
CN1230432C (zh) 取代的苯基－哌嗪衍生物及其制备和用途
CN1147248A (zh) N-(3-吡咯烷基)苯甲酰胺衍生物
CN1154483C (zh) 胺化合物用于制备阻止肿瘤细胞增殖的药物
CN1087741C (zh) 新型吲哚和吲唑化合物,其制备方法及含有它们的药物组合物
CN1589261A (zh) 哌啶衍生物及其作为趋化因子受体(尤其是ccr5)活性调节剂的用途
CN1111528C (zh) 用作神经激肽拮抗药的哌嗪衍生物
CN1225465C (zh) 新化合物
CN1849307A (zh) 作为5－ht1f激动剂的取代的2－羰基氨基－6－哌啶氨基吡啶和取代的1－羰基氨基－3－哌啶氨基苯
CN1185227C (zh) 新化合物
CN1665812A (zh) 用于治疗肥胖的作为选择性黑色素浓缩激素受体拮抗剂的螺取代的哌啶化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1023996

Country of ref document: HK

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee